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The specialty of nuclear medicine is living and well. The
number of scientific presentations at the annual meeting of
the Society of Nuclear Medicine (SNM) in the United States
has increased linearly over the past half century. The excite-
ment and progress resulting from the application of the tra-
cer principle in living human beings continues. 
Oncology is still the major topic in nuclear medicine, fol-
lowed by neurosciences and cardiology. Among the major
applications were those contributing prognosis, treatment
decisions, and documenting the responses to treatment. There
has been a continual growth in positron emission tomogra-
phy (PET) applications, while the number of single photon
emission computed tomography (SPECT) presentations has
been relatively constant at a high level. One of the major
trends in nuclear medicine today is the growth of SPECT/
CT.
18F remains the dominant radionuclide, with 710 presenta-
tions at the SNM meeting: 545 being FDG (fluorodcoxy-
glucose); 118 presentations involved C-11. Technetium was
the topic in 301 papers, with 131I, the old reliable, being there
for 95 papers. 
Another major trend is the increase of imaging of animals
with a dedicated animal device. One hundred studies were
based on a dedicated PET imaging device; about 40 were
based on a SPECT imaging system. There were 5 PET/CT
papers for small animals, but 11 presentations involved
SPECT/CT. 
There has been a plateau over the last 10 yr in the use of
SPECT, which in the past has raised the possibility that nu-
clear medicine in the future will be based primarily on PET
tracers. Today we can see that single photon tracers are alive
and well. New instruments include high-sensitivity, multi-
pinhole SPECT with submillimeter resolution. It is possible
to get virtually limitless resolution with single photon trac-
ers, whereas with a PET tracer being a plus tracer, there is a
finite range of the positrons in tissue before annihilation
occurs and 511 kev photons are emitted. 
SPECT is now becoming added to tissue sampling and
autoradiography by pharmaceutical companies and academ-
ic pharmaceutical laboratories. A new instrument consists
of 4 banks of 9 pinholes; the spatial resolution is 1 mm. A
left ventricular aneurysm was seen in the beating heart of a
mouse. Some new devices have the ability to perform both
PET/CT and SPECT/CT in the same hybrid system for small
animals. The industry has now incorporated all 3 modalities
into a single instrument. 
Molecular imaging is developing a knowledge-based health
care system. We no longer consider only the costs of space,
labor, and capital investment. We now consider the econo-
mic value of the knowledge that our studies provide. 
An example of the need for valuable knowledge is the fact
that in the United States there are 95 million visits to emer-
gency rooms each year. Eight million of those visits are by
patients who complain of chest pain (8.4% of total visits).
Sixty percent of those patients are admitted to a main hos-
pital or in some institutions to a chest pain unit, but only
1.3% turn out to have acute myocardial infarction-the pri-
mary reason patients are admitted to the hospital. The sav-
ings of the costs of unnecessary hospitalization of these pa-
tients could be used for the care of other patients, to support
research, and to justify further development of expensive
technology.
In molecular imaging and therapy, we define disease by
relating the patient’s genome, body structures, histopathol-
ogy, and cellular chemistry to his or her problems, present
or future. We design therapeutic drugs by defining disease
at the cellular and molecular level. We treat the disease by
correcting abnormal cellular or molecular processes. We ex-
press disease manifestations in units of micromoles/minute/
milliliter of disease tissue.
Molecules circulate around our body until they bump into
recognition sites. If they fit in spaces in these recognition
sites, they stick and then produce a biological effect. The
recognition sites decrease the entropy or randomness of all
the circulating molecules in our body-the recognition sites
decrease molecular randomness. Molecular imaging, genet-
ics, and pharmacology are being woven together to create a
new, knowledge-based health care system. 
In what I call the ‘‘the pragmatic paradigm of molecular
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also served as the first publisher of JKMS.imaging’’, we do not confine the patient to a diagnostic box,
such as schizophrenia, depression, arthritis, etc. We make
cellular and molecular dysfunction the basis of diagnosis and
treatment. Pragmatism says, ‘‘Even if you don’t know the
cause of the disease, as is often the case, if you provide the
right treatment, the problem can be addressed.’’
An example of the impact of molecular imaging on health
care is the role of 99mTc-ECD (ethylcysteinate dimer)-brain
SPECT in the evaluation of patients with dementia and mild
cognitive impairment (MCI). In a prospective clinical trial,
magnetic resonance (MR) imaging showed only mild corti-
cal atrophy in some patients. SPECT was able to localize the
abnormalities to a specific area, whereas MR imaging revealed
nonspecific generalized cortical atrophy in most of the cases. 
In 1890, in his classic book Principles of Psychology, Will-
iam James said, ‘‘We need to know a little better what are
the molecular changes in the brain on which thought de-
pends.’’ What William James imagined, we can now image.
In 1945, total brain whole blood flow was measured by Kety
and Schmidt at the University of Pennsylvania. In 1983, the
first dopamine receptor imaging was carried out by PET.
Since that time, in the 2006 SNM program there were 74
presentations on dopamine (4.64% of the total). 
Localization of function in the brain was first described in
1861 by Broca and in 1874 by Wernicke. fMRI blood oxy-
gen leval dependent (BOLD) technology measures the pat-
terns of regional brain blood flow and helps select regions of
interest for a further study-this is the nuclear medicine view-
point of the BOLD study. Psychologists and others like to
see the different patterns that occur in different behavioral
states, but this is all just related to the structure. PET/CT
and SPECT/CT look at the chemistry lying beneath the ter-
rain of the brain-the terrain in many cases being selected by
the technology, either the PET/CT or SPECT/CT, by itself
or by associated fMRI BOLD images.
For decades I have been promoting simple devices where
the problem does not require high resolution in terms of
location. We used a simple, two-detector system in a peer-
reviewed study that resulted in approval of the drug nalme-
fine. We were able to show that nalmefine blocked opiate
receptors with a half-time of 12 hr, whereas naloxone, the
drug widely used in postoperative patients after narcotic
anesthesia, blocked the receptors for only 2 hr. The dual
detector study provided objective evidence that resulted in
the FDA approval of the drug. Every psychiatrist needs a
dual detector nuclear probe system to plan and monitor the
effects of drug therapy.
Another receptor is the cerebral nicotinic acetylcholine
receptor (nAChR) that was shown in studies of the periven-
tricular white matter in patients with Alzheimer disease
(AD) compared with in those with another variant of demen-
tia, vascular dementia (VaD). And it was found that there is
a deficit in different cortical regions in nAChrs in both AD
and VaD, indicating that both have abnormalities in cholin-
ergic neurotransmission. The availability of these receptors
in the periventricular white matter is reduced in VaD but is
normal in AD. This helps differentiate amongVaD, AD,
and other forms of dementia.
Again, going back to functional mental activities, there is
a study of acetylcholine-esterase imaging of brainstem nuclei
in sleep disturbance associated with AD. The researchers
found that sleep disturbances in AD are associated with a
cholinergic impairment in brainstem nuclei.
A classmate of mine at Johns Hopkins was the late George
Glenner, who was the person who studied the chemistry of
amyloid. He reported the discovery in 1984 that the plaques
that we see in AD, first described by Alzheimer himself, con-
sist of amyloid. This has resulted in a tremendous body of
research.
Our hypothesis is that beta amyloid imaging would allow
earlier and more specific diagnosis of AD, allowing earlier
intervention and specific therapy. What we need now are
longitudinal studies on large populations beginning with
people who are totally asymptomatic to define when the
process of plaque formation begins in the development of
dementia. The question arises whether molecular imaging
will be used in screening. 
What’s new in cardiology? Image fusion clearly is a major
area of research. From 2003 to 2005, the number of presen-
tations at the SNM meeting rose from 19 to 41. I was eager-
ly waiting to see what the number of SPECT/CT presenta-
tions would be this year-it turned out to be 65. This year I
chose as the Images of the Year: a 99mTc-tetrofosmin blood
flow study fused with a 64-slice CT angiography (CTA)
study. This study is an example of ‘‘software’’ fusion. Many
patients with visible stenotic lesions in their coronary arter-
ies were found to have no abnormalities of myocardial per-
fusion.
Keidar et al. assessed hemodynamically significant coro-
nary artery lesions with an integrated SPECT/CT device,
called a ‘‘hybrid’’ system, with fusion of the SPECT and CTA
with the patient in the same gantry. CTCA alone, which is
currently being widely used in screening patients for coro-
nary artery disease (CAD), has a good negative predictive
value. If you have a normal finding, there is a very high prob-
ability that you do not have CAD. But if you have abnor-
mal findings on CTCA, there is only a 31% possibility that
you have an associated reduction in regional myocardial blood
flow. 
Ask yourself, if you or a loved one had severe chest pain,
and all of the following studies were available, which would
you choose? 1) CTA; 2) 82Rb PET/CTA; 3) 99mTc-sestamibi
or 201Tl SPECT/CTA; 4) 13N-NH3 PET/ CTA; 5) troponin
serum enzyme measurements; 6) exercise electrocardiogram
(ECG); and 7) exercise SPECT. If you’ve all voted, the correct
answers in my opinion are 2 or 3. And I am sure there will
be many disagreements.
There has been a lot of discussion about the degree of con-
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have advocated the principle that has not yet been widely
accepted but not widely resisted that every person in nucle-
ar medicine should know as much about CT as a diagnostic
radiologist. I believe that every radiologist should know as
much about PET and SPECT as a nuclear medicine physi-
cian. That is, the fusion of the expertise in one person-whether
the nuclear medicine physician or the radiologist.
You can tell with the PET the separation between the res-
ponders and the nonresponders, whereas it took 3 months
before the changes in the MRI.
Double-tracer studies can be done, as in the study by Pau-
leit et al. with fluorethyltyrosine (FET) and 18F-FDG PET
in patients with cerebral gliomas. In this study, 28 patients
had the first scan with FET, then the second scan was per-
formed 30 min afterward, and the FDG uptake was calcu-
lated by subtraction of the FET scan from the FET/FDG
scan. In the FET PET and FDG PET studies, the FET has a
far better contrast with the normal brain than did the FDG
study. 
We need to facilitate and expedite the approval of new
pharmaceuticals and procedures. Perhaps we should incor-
porate diagnostic and efficacy-monitoring tracers in primar-
ily therapeutic clinical trials in order to attract financial sup-
port from pharmaceutical companies and to facilitate regu-
latory approval and reimbursement. We are limited by the
fact that big pharmaceuticals like therapeutic drugs that are
administered over long periods of time. They hesitate to invest
in developing diagnostic tracers that will be used only once
or twice in a given patient. So if you can combine the two,
it may result in safer, more effective, and cheaper pharma-
ceuticals and radiopharmaceuticals.
In summary, while positron-emitting tracers continue to
produce striking results and valuable new knowledge, SP-
ECT/CT is advancing rapidly. Structure/function/biochem-
istry have fused. Dedicated animal scanners, first proposed
in 1987, have been perfected and become widespread in
industry and academia. Medicine has progressively increased
its spatial resolution from whole body to organs to tissues,
and to cells to molecules. What we imagined, we have now
achieved. 
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